A Phase 1/2 interventional study of LDE225 and INC424 in Primary Myelofibrosis, Thrombocytosis and Essential Thrombocythemia, sponsored by Novartis Pharmaceuticals. Completed at 18 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Primary Myelofibrosis by Novartis — 1 open to participants now, 4 under way, 2 of them phase 3. Primary Myelofibrosis · Novartis.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1/2, and was the 10th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →1 of the 24 studies in Primary Myelofibrosis by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 7 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 51 across the 21 interventional studies, 684 across the 2 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Primary Myelofibrosis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the combination and b) to assess the efficacy of the co-administration of LDE225 and INC424 on spleen volume reduction.
The study is considered to have been completed because the participants completed the study as per study design at the time of trial termination. If participants were already in extension phase until discontinuation criteria were met or alternative setting was available, they were considered as completed. The study was terminated due to one of the compounds being divested.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b)
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.
Time frame: 6 weeks (42 days)
Percentage of Patients Achieving >= 35% Reduction in Spleen Volume in Phase Ib Expansion and Phase II Stage 1
Reduction in spleen volume as measured by magnetic resonance imaging/Cat Scan (MRI/CT) in Phase Ib expansion and Phase II Stage 1 patients
Time frame: Week 24 and Week 48
Phase Ib and Phase II: LDE225: Plasma Pharmacokinetics (PK) Parameter: Area Under the Curve(AUC0-24h)
Plasma Concentration Time Curve: AUC0-24h: Area under the concentration-time curve from time zero to 24 hours extrapolate from AUClast\[mass x time x volume-1\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Phase Ib and Phase II: INC424: PK Parameters: Area Under the Curve for AUC0-12h, AUCinf & AUClast
AUC0-12h: Area under the concentration-time curve from time zero to 12 hours extrapolate from AUClast\[mass x time x volume-1\]. AUCinf: Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase \[mass x time x volume-1\]. AUClast: Area under the concentration-time curve from time zero to the time of last measurable concentration \[mass x time x volume-1\].
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Phase Ib and Phase II: LDE225 & INC424: PK Parameter: Maximum Plasma Concentration (Cmax)
Cmax: Maximum observed plasma concentration after drug administration \[mass x volume- 1\].
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Phase Ib and Phase II: LDE225 & INC424: Plasma PK Parameter: Time to Maximum Plasma Concentration (Tmax)
Tmax: Time to reach Cmax \[time\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Phase Ib and Phase II: LDE225 & INC424:: Plasma Pharmacokinetics (PK) Parameters: Area Under the Curve(CL/F)
CL/F: Apparent total plasma clearance of drug after oral administration \[volume x time-1\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1 & Week 9 Day 1
Phase Ib and Phase II: Percentage of Participants With Fibrosis Grade Assessed by Bone Marrow Histomorphology, by Time and Treatment in Phase Ib and Phase II Stage 1
The number of patients experiencing improvement in their bone marrow fibrosis by at least one grade and assessment of cellularity.
Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Phase Ib and Phase ll: Summary of JAK2V617F Allele Burden by Visit and Treatment in Phase Ib and Phase II Stage 1
Phase Ib and Phase ll: Change in Pharmacodynamic Biomarkers: JAK2V617F allele burden
Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Phase Ib and Phase ll: Summary of Cytokine Levels in Pharmacodynamic for All Collected Biomarkers
Summary of cytokine levels in Pharmacodynamic Biomarkers for all 26 collected at Week 25 Day 1 and Week 49 Day 1
Time frame: Baseline, Week 25 Day 1 (Week 24), Week 49 Day 1 (Week 48)
Phase Ib and Phase II: Percentage of Participants With >= 50% Reduction From Baseline in MFSAF Total Symptom Scores
The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.
Time frame: Week 24, Week 48
Phase Ib and Phase II: Change in Total Symptom Score (TSS) From Baseline to Week 25 & Week 49 Using the MFSAF Total Symptom Scores
The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.
Time frame: Baseline, Week 25, Week 49
Phase I and Phase II: Change in EORTC QLQ-C30 Scores From Baseline Compared to Week 24 & Week 48
EORTC QLQ-C30 is the European Organization for Research \& Treatment of Cancer, Quality of Life (QoL) Questionnaire \& is one of the most widely used \& validated instruments to measure health-related QoL in subjects with cancer. The scale includes 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning \& social functioning), global health status/QoL \& 9 symptom scale/items (fatigue, nausea \& vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, \& financial difficulties). This instrument asks the subject to respond according to the past week, with the exception of the first 5 questions that represent physical functioning \& capture the subject's current status. The range of scores for all of the scales is from 0 to 100. For functional \& global health status/QoL scales, higher scores indicate better QoL \& level of functioning; for symptom scales, higher scores indicate greater level of symptoms or difficulties.
Time frame: Week 24, Week 48
Phase Ib and Phase II: LDE225: PK Parameter: Racc
Racc: Accumulation ratio calculated as AUC0-12h on Week 9 Day 1 divided by AUC0-12h on Week 1 Day 1 \[fold\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 9 Day 1
Phase Ib and Phase II: INC424: PK Parameter: T1/2
T1/2: Elimination half-life associated with the terminal slope (lambda_z) of a semi logarithmic concentration-time curve \[time\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1
Phase Ib and Phase II: INC424: PK Parameter: Vss/F
Vss/F: Apparent volume of distribution at steady state after oral administration \[volume\]
Time frame: 0, 0.5, 1. 1.5, 2, 4, 6, 8 hrs on Week 1 Day 1
A total of 50 subjects were enrolled in the study, of which 23 subjects were enrolled in Phase Ib part of dose-escalation phase and 27 subjects were enrolled in Phase Ib dose-expansion phase and Phase II Stage 1.
| Milestone | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15 mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Started | 8 | 10 | 5 | 27 |
| Completed | 0 | 1 | 0 | 0 |
| Not completed | 8 | 9 | 5 | 27 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 4 |
| Withdrew: Physician decision | 2 | 2 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 5 | 2 | 16 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 3 |
| Withdrew: Progressive disease | 2 | 2 | 1 | 1 |
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.
| Participants | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Blood creatine phosphokinase increased | 0 | 2 | 0 | 1 |
Reduction in spleen volume as measured by magnetic resonance imaging/Cat Scan (MRI/CT) in Phase Ib expansion and Phase II Stage 1 patients
| Percentage of Participants | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|
| Week 24 | 44.4 |
| Week 48 | 29.6 |
Plasma Concentration Time Curve: AUC0-24h: Area under the concentration-time curve from time zero to 24 hours extrapolate from AUClast\[mass x time x volume-1\]
| ng*hr/mL | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| LDE225 (Week 1, Day 1) (n=6,10,4,24) | 2680 ± 33.1 | 1900 ± 100.4 | 1090 ± 84.0 | 2060 ± 78.7 |
| LDE225 (Week 9, Day 1) (n=6,6,4,14) | 15500 ± 31.8 | 13000 ± 66.8 | 17100 ± 30.8 | 14500 ± 45.4 |
AUC0-12h: Area under the concentration-time curve from time zero to 12 hours extrapolate from AUClast\[mass x time x volume-1\]. AUCinf: Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase \[mass x time x volume-1\]. AUClast: Area under the concentration-time curve from time zero to the time of last measurable concentration \[mass x time x volume-1\].
| ng*hr/mL | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| AUC0-12h: Wk1 Day 1 (n=8,10,5,25) | 473 ± 29.5 | 805 ± 45.6 | 1130 ± 23.0 | 1190 ± 41.0 |
| AUC0-12h: Wk 9 Day 1 (n=8,9,4,20) | 489 ± 42.5 | 835 ± 46.6 | 962 ± 23.7 | 1230 ± 42.4 |
| AUCinf: Wk1 Day 1 (n=7,9,4,16) | 466 ± 30.9 | 789 ± 46.1 | 1140 ± 28.0 | 1130 ± 47.7 |
| AUCinf: Wk 9 Day 1 (n=8,9,3,15) | 498 ± 43.1 | 867 ± 48.7 | 978 ± 29.5 | 1140 ± 43.0 |
| AUClast: Wk1 Day 1 (n=8,10,5,26) | 443 ± 26.2 | 730 ± 39.7 | 1030 ± 20.8 | 1070 ± 38.6 |
| AUClast: Wk 9 Day 1 (n=8,9,4,20) | 460 ± 44.3 | 776 ± 43.9 | 891 ± 24.3 | 1130 ± 38.6 |
Cmax: Maximum observed plasma concentration after drug administration \[mass x volume- 1\].
| ng/mL | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| LDE225 (Week 1, Day 1) (n=6,10,5,26) | 311 ± 35.1 | 221 ± 103.4 | 161 ± 94.9 | 251 ± 83.4 |
| LDE225 (Week 9, Day 1) (n=8,8,5,20) | 879 ± 38.0 | 720 ± 57.5 | 959 ± 39.4 | 951 ± 51.1 |
| INC424 (Week 1, Day 1) (n=8,10,5,27) | 154 ± 29.0 | 244 ± 40.4 | 351 ± 27.7 | 338 ± 40.1 |
| INC424 (Week 9, Day 1) (n=8,9,4,20) | 168 ± 38.8 | 269 ± 33.2 | 281 ± 36.5 | 350 ± 36.0 |
Tmax: Time to reach Cmax \[time\]
| hour (hr) | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| LDE225 (Week 1, Day 1) (n=6,10,5,26) | 3.01 (2.00 to 4.00) | 2.08 (1.50 to 4.22) | 2.00 (1.50 to 8.00) | 2.00 (1.00 to 6.00) |
| LDE225 (Week 9, Day 1) (n=8,8,5,20) | 1.79 (0.170 to 4.00) | 2.00 (1.50 to 4.00) | 2.00 (1.50 to 6.00) | 3.21 (1.50 to 23.9) |
| INC424 (Week 1, Day 1) (n=8,10,5,27) | 0.500 (0.500 to 2.00) | 0.575 (0.330 to 2.03) | 0.500 (0.500 to 0.970) | 0.580 (0.420 to 4.00) |
| INC424 (Week 9, Day 1) (n=8,9,4,20) | 0.875 (0.170 to 1.50) | 0.500 (0.500 to 1.52) | 1.00 (0.500 to 1.00) | 1.00 (0.330 to 2.00) |
CL/F: Apparent total plasma clearance of drug after oral administration \[volume x time-1\]
| L/hr | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| LDE225 (Week 1, Day 1) (n=5,5,1,12) | 145 (120 to 166) | 238 (53.7 to 508) | 727 (727 to 727) | 122 (46.2 to 525) |
| LDE225 (Week 9, Day 1) (n=6,6,4,14) | 27.8 (14.9 to 35.7) | 34.5 (12.9 to 62.3) | 25.1 (15.4 to 30.9) | 27.0 (12.6 to 56.9) |
| INC424 (Week 1, Day 1) (n=7,9,4,16) | 23.8 (12.2 to 26.9) | 18.7 (9.04 to 39.0) | 16.5 (13.3 to 25.6) | 16.9 (7.54 to 35.0) |
The number of patients experiencing improvement in their bone marrow fibrosis by at least one grade and assessment of cellularity.
| Percentage of Participants | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Baseline, grade 0 (n=0,0,0,1) | — | — | — | 3.7 |
| Baseline, grade 1 (n=0,1,0,4) | — | 10.0 | — | 14.8 |
| Baseline, grade 2 (n=4,6,3,8) | 50.0 | 50.0 | 60.0 | 29.6 |
| Baseline, grade 3 (n=3,3,0,8) | 37.5 | 30.0 | — | 29.6 |
| Baseline, missing grade (n=1,0,2,6) | 12.5 | — | 40.0 | 22.2 |
| Week 25 Day 1, grade 1 (n=1,1,0,1) | 12.5 | 10.0 | — | 3.7 |
| Week 25 Day 1, grade 2 (n=0,3,2,7) | — | 30.0 | 40.0 | 25.9 |
| Week 25 Day 1, grade 3 (n=5,4,1,5) | 62.5 | 40.0 | 20.0 | 18.5 |
| Week 25 Day 1, missing grade (n=2,2,2,14) | 25.0 | 20.0 | 40.0 | 51.9 |
| Week 49 Day 1, grade 0 (n=0,0,0,1) | — | — | — | 3.7 |
| Week 49, Day 1 grade 1 (n=0,0,0,1) | — | — | — | 3.7 |
| Week 49 Day 1, grade 2 (n=0,1,1,2) | — | 10.0 | 20.0 | 7.4 |
| Week 49 Day 1, grade 3 (n=2,2,2,3) | 25.0 | 20.0 | 40.0 | 11.1 |
| Week 49 Day 1, missing grade (n=6,7,2,20) | 75.0 | 70.0 | 40.0 | 74.1 |
Phase Ib and Phase ll: Change in Pharmacodynamic Biomarkers: JAK2V617F allele burden
| Percentage of JAK allele burden mutation | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Baseline | 84.7 (48.4 to 95.1) | 61.7 (2.5 to 92.1) | 88.3 (52.7 to 94.4) | 55.4 (2.5 to 93.5) |
| Week 25 Day 1 (n=7,6,5,21) | 88.6 (49.8 to 94.1) | 48.0 (2.5 to 78.4) | 74.9 (52.1 to 89.6) | 43.8 (2.5 to 93.9) |
| Week 49 Day 1 (n=4,3,4,13) | 86.0 (20.1 to 94.1) | 54.3 (2.5 to 80.0) | 75.7 (56.9 to 90.0) | 46.1 (2.5 to 85.6) |
Summary of cytokine levels in Pharmacodynamic Biomarkers for all 26 collected at Week 25 Day 1 and Week 49 Day 1
| ng/mL | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| AFP: Week 25 Day 1 (Wk 25 D1) (n=7,8,5,22) | 0.75 (0.3 to 2.5) | 0.79 (0.3 to 1.4) | 1.10 (0.3 to 2.2) | 0.49 (0.49 to 2.0) |
| AFP: Week 49 Day 1 (WK25 D1) (n=4,3,4,14) | 0.68 (0.3 to 1.6) | 0.60 (0.5 to 0.9) | 0.49 (0.49 to 1.1) | 0.49 (0.49 to 2.6) |
| APOA-1: Week 25 Day 1 (n=7,8,5,22) | 1.10 (0.7 to 1.7) | 1.65 (1.0 to 2.2) | 1.60 (1.2 to 1.6) | 2.10 (1.5 to 3.8) |
| APOA-1: Week 49 Day 1 (n=4,3,4,14) | 1.30 (0.9 to 1.5) | 1.50 (1.0 to 2.9) | 1.80 (1.6 to 2.6) | 2.05 (1.4 to 3.1) |
| B2M: Week 25 Day 1 (n=7,8,5,22) | 5.00 (2.8 to 7.4) | 3.15 (2.1 to 5.9) | 3.70 (2.4 to 5.2) | 3.15 (1.8 to 7.2) |
| B2M: Week 49 Day 1 (n=4,3,4,14) | 5.75 (4.5 to 11.0) | 4.60 (1.9 to 6.1) | 3.25 (2.4 to 4.4) | 3.00 (1.0 to 6.3) |
| BDNF: Week 25 Day 1 (n=7,8,5,22) | 0.46 (0.0 to 2.0) | 0.85 (0.2 to 2.5) | 0.15 (0.1 to 0.4) | 0.55 (0.0 to 2.7) |
| BDNF: Week 49 Day 1 (n=4,3,4,14) | 1.16 (0.3 to 2.4) | 0.19 (0.0 to 3.8) | 0.41 (0.0 to 5.6) | 0.52 (0.0 to 12.0) |
| C Reactive Protein: Week 25 Day 1 (n=7,8,5,22) | 2.60 (1.0 to 16.0) | 2.70 (0.3 to 51.0) | 1.30 (0.1 to 4.1) | 4.50 (0.1 to 182.0) |
| C Reactive Protein: Week 49 Day 1 (n=4,3,4,14) | 4.65 (0.4 to 9.0) | 2.40 (0.0 to 6.3) | 1.30 (0.7 to 2.5) | 0.79 (0.1 to 30.0) |
| Carcinoembryyonic Antigen: Wk 25 D1 (n=7,8,5,22) | 1.40 (0.3 to 58.0) | 1.20 (0.8 to 5.6) | 1.20 (0.3 to 3.4) | 1.80 (0.2 to 12.0) |
| Carcinoembryyonic Antigen: Wk 49 D1 (n=4,3,4,14) | 1.72 (0.8 to 3.7) | 1.20 (1.1 to 1.3) | 1.45 (0.5 to 2.6) | 1.80 (0.5 to 12.0) |
| Cluster of. Diff 40: Wk 25 D1 (n=7,7,5,0) | 1.90 (0.8 to 3.4) | 1.10 (0.6 to 1.6) | 0.91 (0.6 to 1.4) | — |
| Cluster of. Diff 40: Wk 49 D1 (n=4,2,0,0) | 1.65 (0.9 to 2.4) | 1.3 (1.2 to 1.4) | — | — |
| Eotaxin1: Wk 25 D1 (n=7,8,5,22) | 155.00 (42.5 to 214.0) | 119.00 (42.5 to 429.0) | 101.00 (42.5 to 152.0) | 118.00 (58.5 to 294.0) |
| Eotaxin1: Wk 49 D1 (n=4,3,4,14) | 136.00 (42.5 to 290.0) | 145.00 (58.5 to 622.0) | 157.00 (58.5 to 380.0) | 175.00 (58.5 to 360.0) |
| ICAM1: Wk 25 D1 (n=7,8,5,22) | 266.00 (139.0 to 451.0) | 203.00 (137.0 to 339.0) | 168.00 (82.0 to 316.0) | 185.50 (93.0 to 324.0) |
| ICAM1: Wk 49 D1 (n=4,3,4,14) | 321.00 (95.0 to 470.0) | 173.00 (94.0 to 193.0) | 152.50 (91.0 to 553.0) | 163.00 (92.0 to 310.0) |
| IL10: Wk 25 D1 (n=7,8,5,22) | 9.30 (6.9 to 21.0) | 7.50 (3.4 to 11.0) | 3.40 (3.4 to 12.0) | 6.23 (4.1 to 29.0) |
| IL10: Wk 49 D1 (n=4,3,4,14) | 8.10 (3.4 to 12.0) | 4.05 (3.4 to 18.0) | 11.00 (8.4 to 24.0) | 8.40 (4.1 to 28.0) |
| IL18: Wk 25 D1 (n=7,8,5,22) | 292.00 (132.0 to 520.0) | 220.50 (108.0 to 907.0) | 445.00 (161.0 to 687.0) | 415.50 (127.0 to 1160.0) |
| IL18: Wk 49 D1 (n=4,3,4,14) | 278.00 (146.0 to 606.0) | 199.00 (168.0 to 575.0) | 550.50 (313.0 to 1260.0) | 318.50 (134.0 to 886.0) |
| IL1B: Wk 25 D1 (n=7,8,5,22) | 3.30 (3.3 to 3.3) | 3.30 (3.3 to 4.3) | 3.30 (3.3 to 6.9) | 4.3 (4.3 to 16.0) |
| IL1B: Wk 49 D1 (n=4,3,4,14) | 3.30 (3.3 to 3.3) | 3.30 (3.3 to 4.3) | 4.3 (4.3 to 8.9) | 4.3 (4.3 to 10.0) |
| IL1RN: Wk 25 D1 (n=7,8,5,22) | 130.00 (92.0 to 218.0) | 147.00 (85.0 to 496.0) | 114.00 (89.0 to 183.0) | 88.00 (63.0 to 328.0) |
| IL1RN: Wk 49 D1 (n=4,3,4,14) | 98.00 (71.0 to 124.0) | 281.00 (29.5 to 782.0) | 88.00 (73.0 to 214.0) | 85.50 (29.5 to 162.0) |
| IL6: Wk 25 D1 (n=7,8,5,22) | 4.70 (2.3 to 6.8) | 2.3 (2.3 to 6.3) | 2.3 (2.3 to 6.0) | 3.40 (3.4 to 11.0) |
| IL6: Wk 49 D1 (n=4,3,4,14) | 3.48 (2.3 to 6.8) | 3.40 (2.3 to 4.7) | 3.40 (3.4 to 11.0) | 3.40 (3.4 to 7.3) |
| IL8: Wk 25 D1 (n=7,8,5,22) | 28.00 (15.0 to 84.0) | 9.50 (7.2 to 74.0) | 15.00 (10.0 to 34.0) | 29.50 (6.9 to 280.0) |
| IL8: Wk 49 D1 (n=4,3,4,14) | 18.50 (9.6 to 161.0) | 11.00 (8.4 to 19.0) | 58.50 (19.0 to 166.0) | 32.00 (3.1 to 261.0) |
| Insulin: Wk 25 D1 (n=7,8,5,22) | 2.70 (0.8 to 5.4) | 1.35 (0.6 to 3.3) | 2.30 (1.8 to 3.8) | 0.6 (0.6 to 8.9) |
| Insulin: Wk 49 D1 (n=4,3,4,14) | 2.90 (1.4 to 3.1) | 2.90 (0.6 to 4.9) | 1.65 (0.6 to 3.0) | 1.60 (0.6 to 14.0) |
| LEP: Wk 25 D1 (n=7,8,5,22) | 1.50 (0.7 to 34.0) | 4.75 (1.2 to 30.0) | 6.00 (3.4 to 6.1) | 6.40 (1.2 to 49.0) |
| LEP: Wk 49 D1 (n=4,3,4,14) | 3.45 (0.7 to 16.0) | 17.00 (2.7 to 29.0) | 5.95 (1.0 to 10.0) | 5.60 (3.3 to 28.0) |
| Macro. Inflam. Prot-1 Beta: Wk 25 D1 (n=7,8,5,22) | 491.00 (269.0 to 1160.0) | 375.50 (203.0 to 1260.0) | 410.00 (330.0 to 873.0) | 513.00 (190.0 to 1010.0) |
| Macro. Inflam. Prot-1 Beta: Wk 49 D1 (n=4,3,4,14) | 406.50 (242.0 to 758.0) | 487.00 (357.0 to 594.0) | 970.50 (489.0 to 1850.0) | 521.00 (159.0 to 1100.0) |
| Macro.-derived Chemokine: Wk 25 D1 (n=7,8,5,22) | 253.00 (43.0 to 599.0) | 274.00 (93.0 to 1040.0) | 516.00 (193.0 to 1100.0) | 254.00 (55.0 to 760.0) |
| Macro.-derived Chemokine: Wk 49 D1 (n=4,3,4,14) | 190.50 (9.5 to 852.0) | 327.00 (218.0 to 963.0) | 430.50 (132.0 to 801.0) | 212.00 (97.0 to 696.0) |
| MPO: Wk 25 D1 (n=7,8,5,22) | 327.00 (127.0 to 1600.0) | 323.00 (134.0 to 3120.0) | 335.00 (134.0 to 3350.0) | 164.50 (63.0 to 1310.0) |
| MPO: Wk 49 D1 (n=4,3,4,14) | 175.00 (87.0 to 377.0) | 180.00 (122.0 to 1340.0) | 237.00 (147.0 to 794.0) | 116.50 (43.0 to 1760.0) |
| Myoglobin: Wk 25 D1 (n=7,8,5,22) | 31.00 (19.0 to 51.0) | 31.50 (16.0 to 47.0) | 54.00 (28.0 to 112.0) | 39.50 (16.0 to 140.0) |
| Myoglobin: Wk 49 D1 (n=4,3,4,14) | 35.00 (13.0 to 47.0) | 18.00 (14.0 to 49.0) | 45.50 (31.0 to 55.0) | 45.00 (14.0 to 76.0) |
| Plasmin. Activ. Inhibitor 1: Wk 25 D1 (n=7,8,5,22) | 34.00 (13.0 to 52.0) | 45.50 (9.2 to 73.0) | 17.00 (12.0 to 41.0) | 51.50 (5.5 to 240.0) |
| Plasmin. Activ. Inhibitor 1: Wk 49 D1 (n=4,3,4,14) | 31.50 (12.0 to 42.0) | 25.00 (13.0 to 80.0) | 49.00 (14.0 to 117.0) | 52.50 (21.0 to 226.0) |
| RANTES: Wk 25 D1 (n=7,8,5,22) | 4.80 (1.6 to 15.0) | 5.85 (1.6 to 18.0) | 4.20 (1.8 to 13.0) | 8.80 (0.3 to 37.0) |
| RANTES: Wk 49 D1 (n=4,3,4,14) | 8.25 (3.4 to 14.0) | 3.20 (0.7 to 14.0) | 10.55 (0.9 to 35.0) | 6.50 (0.8 to 73.0) |
| Thyroxine binding globulin Wk 25 D1 (n=7,8,5,22) | 38.00 (31.0 to 47.0) | 41.50 (30.0 to 75.0) | 45.00 (40.0 to 67.0) | 54.50 (33.0 to 82.0) |
| Thyroxine binding globulin: Wk 49 D1 (n=4,3,4,14) | 42.00 (29.0 to 58.0) | 45.00 (38.0 to 51.0) | 72.50 (71.0 to 76.0) | 54.00 (37.0 to 76.0) |
| TNFA: Wk 25 D1 (n=7,8,5,22) | 27.00 (7.0 to 77.0) | 18.50 (7.0 to 79.0) | 25.00 (16.0 to 38.0) | 12.00 (12.0 to 319.0) |
| TNFA: Wk 49 D1 (n=4,3,4,14) | 32.50 (7.0 to 57.0) | 32.00 (12.0 to 51.0) | 26.50 (12.0 to 112.0) | 12.00 (12.0 to 79.0) |
| TNFRT 2: Wk 25 D1 (n=7,8,5,22) | 33.00 (16.0 to 36.0) | 12.00 (6.2 to 53.0) | 15.00 (7.8 to 30.0) | 17.50 (5.9 to 40.0) |
| TNFRT 2: Wk 49 D1 (n=4,3,4,14) | 28.00 (21.0 to 38.0) | 21.00 (5.5 to 29.0) | 16.00 (12.0 to 27.0) | 12.50 (3.8 to 33.0) |
| VCAM1: Wk 25 D1 (n=7,8,5,22) | 2040.00 (1200.0 to 3420.0) | 1130.00 (809.0 to 2830.0) | 1690.00 (986.0 to 2770.0) | 1930.00 (984.0 to 3760.0) |
| VCAM1: Wk 49 D1 (n=4,3,4,14) | 2425.00 (1200.0 to 3220.0) | 1210.00 (1160.0 to 2230.0) | 2225.00 (1410.0 to 3050.0) | 1715.00 (1030.0 to 3260.0) |
| VEGF: Wk. 25 D1 (n=7,8,5,22) | 145.00 (132.0 to 429.0) | 202.50 (133.0 to 301.0) | 108.00 (64.0 to 113.0) | 168.00 (86.0 to 469.0) |
| VEGF: Wks. 49 D1 (n=4,3,4,14) | 227.00 (56.0 to 286.0) | 106.00 (83.0 to 223.0) | 163.00 (87.0 to 406.0) | 217.00 (87.0 to 543.0) |
| VWF: Wk. 25 D1 (n=7,8,5,22) | 135.00 (78.0 to 726.0) | 65.50 (34.0 to 140.0) | 398.00 (81.0 to 1540.0) | 156.50 (26.0 to 1230.0) |
| VWF: Wk. 49 D1 (n=4,3,4,14) | 140.50 (26.0 to 385.0) | 67.00 (37.0 to 110.0) | 716.00 (25.0 to 2200.0) | 154.50 (28.0 to 2290.0) |
The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.
| Percentage of participants | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Week 24 | 50.00 (15.70 to 84.30) | 40.0 (12.16 to 73.76) | 80.0 (28.36 to 99.49) | 33.3 (16.52 to 53.96) |
| Week 48 | 25.00 (3.19 to 65.09) | 20.0 (2.52 to 55.61) | 80.0 (28.36 to 99.49) | 18.5 (6.30 to 38.08) |
The 7-day modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. The first 6 items assess MF symptom severity at its worst as recalled in the 7 days prior to the clinic visit assessment. The symptoms measured include night sweats, itching, abdominal discomfort, pain under the ribs (left side), early satiety, \& bone/muscle pain. The 7th item captures MF-related inactivity in the past 7 days prior to the clinic visit assessment. All 7 items ask subjects to record their answers on an 11-point numeric rating scale (NRS), (0 = Absent, 10 = Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score.
| scores on a scale | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Week 25 (n = 6, 7, 5, 19) | -18.8 ± 15.20 | -14.0 ± 8.58 | -19.4 ± 6.43 | -6.5 ± 9.26 |
| Week 49 (n = 4, 5, 4, 10) | -18.5 ± 12.07 | -13.6 ± 10.43 | -21.0 ± 5.66 | -8.0 ± 14.61 |
EORTC QLQ-C30 is the European Organization for Research \& Treatment of Cancer, Quality of Life (QoL) Questionnaire \& is one of the most widely used \& validated instruments to measure health-related QoL in subjects with cancer. The scale includes 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning \& social functioning), global health status/QoL \& 9 symptom scale/items (fatigue, nausea \& vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, \& financial difficulties). This instrument asks the subject to respond according to the past week, with the exception of the first 5 questions that represent physical functioning \& capture the subject's current status. The range of scores for all of the scales is from 0 to 100. For functional \& global health status/QoL scales, higher scores indicate better QoL \& level of functioning; for symptom scales, higher scores indicate greater level of symptoms or difficulties.
| scores on a scale | LDE225 400mg + INC424 10mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Glob. Health Status/Qol: Wk 25 (n=6,7,5,19) | -2.8 ± 21.52 | -2.4 ± 21.90 | 16.7 ± 27.64 | 2.6 ± 22.75 |
| Glob. Health Status/Qol: Wk 49(n=4,4,4,10) | -2.1 ± 23.94 | 14.6 ± 45.33 | -0.0 ± 20.41 | -3.3 ± 24.91 |
| Phys. Func: Wk 25 (n=6,7,5,19) | 15.6 ± 25.88 | -1.0 ± 14.10 | 17.3 ± 16.73 | 1.0 ± 23.74 |
| Phys. Func: Wk 49 (n=4,4,4,10) | 25.0 ± 16.67 | -10.0 ± 25.82 | 15.0 ± 22.03 | 6.0 ± 15.85 |
| Role Func: Wk 25 (n=6,7,5,19) | 33.3 ± 39.44 | -7.1 ± 18.90 | 16.7 ± 20.41 | 7.9 ± 32.09 |
| Role Func: Wk 49 (n=4,4,4,10) | 41.7 ± 21.52 | -33.3 ± 27.22 | 12.5 ± 25.00 | 10.2 ± 22.50 |
| Emo. Func: Wk 25 (n=6,7,5,19) | 25.0 ± 16.67 | -8.3 ± 31.18 | 5.6 ± 12.42 | 2.5 ± 18.61 |
| Emo. Func: Wk 49 (n=4,4,4,10) | 33.3 ± 11.79 | -12.5 ± 41.67 | 0.0 ± 15.21 | -2.5 ± 10.43 |
| Cog. Func: Wk 25 (n=6,7,5,19 | 14.6 ± 18.77 | -6.3 ± 19.80 | -3.3 ± 13.94 | 2.6 ± 18.64 |
| Cog. Func: Wk 49 (n=4,4,4,10) | 20.8 ± 15.96 | -8.3 ± 28.87 | 4.2 ± 8.33 | -5.0 ± 22.29 |
| Soc. Func: Wk 25 (n=6,7,4,19) | 8.3 ± 39.09 | -7.1 ± 18.90 | 12.5 ± 15.96 | -2.6 ± 24.38 |
| Soc. Func: Wk 49 (n=3,4,4,10) | 16.7 ± 16.67 | -4.2 ± 8.33 | 12.5 ± 25.00 | -3.3 ± 18.92 |
| Fatigue: Wk 25 (n=6,7,5,19) | -20.4 ± 25.74 | -1.6 ± 26.78 | -28.9 ± 16.85 | -8.8 ± 26.86 |
| Fatigue: Wk 49 (n=4,4,4,10) | -27.8 ± 6.42 | 0. ± 15.71 | -33.3 ± 18.14 | 4.4 ± 36.74 |
| Naus & Vom: Wk 25 (n=6,7,5,19) | -5.6 ± 13.61 | -4.8 ± 18.54 | -3.3 ± 7.45 | -3.5 ± 11.89 |
| Naus & Vom: Wk 49 (n=4,4,4,10) | -4.2 ± 15.96 | 4.2 ± 28.46 | 0.0 ± 13.61 | -10.0 ± 11.65 |
| Pain: Wk 25 (n=6,7,5,18) | -11.1 ± 40.37 | -4.8 ± 38.14 | -26.7 ± 25.28 | -8.3 ± 21.58 |
| Pain: Wk 49 (n=4,4,4,10) | 25.0 ± 21.52 | -8.3 ± 56.93 | -20.8 ± 25.00 | 3.3 ± 10.54 |
| Dyspnoea: Wk 25 (n=6,7,5,19) | -33.3 ± 29.81 | -4.8 ± 29.99 | -6.7 ± 14.91 | -1.8 ± 26.00 |
| Dyspnoea: Wk 49 (n=4,4,4,10) | -33.3 ± 27.22 | -16.7 ± 43.03 | 0.0 ± 0.00 | 6.7 ± 26.29 |
| Insomnia: Wk 25 (n=6,7,5,19) | -22.2 ± 27.22 | 0.0 ± 38.49 | -33.3 ± 23.57 | -17.5 ± 34.01 |
| Insomnia: Wk 49 (n=4,4,4,10) | -25.0 ± 31.91 | 8.3 ± 16.67 | -33.3 ± 27.22 | -33.3 ± 41.57 |
| Appetite loss: Wk 25 (n=6,7,5,19) | -27.8 ± 25.09 | 4.8 ± 12.60 | -13.3 ± 18.26 | -12.3 ± 29.84 |
| Appetite loss: Wk 49 (n=4,4,4,10) | -25.0 ± 41.94 | 8.3 ± 16.67 | -16.7 ± 19.25 | 0.0 ± 44.44 |
| Constipation: Wk 25 (n=6,7,5,19) | -11.1 ± 17.21 | 0.0 ± 0.00 | 13.3 ± 29.81 | 7.0 ± 30.59 |
| Constipation: Wk 49 (n=4,4,4,10) | -33.3 ± 47.14 | 0.0 ± 27.22 | 8.3 ± 16.67 | 3.3 ± 36.68 |
| Diarrhoea: Wk 25 (n=6,7,5,19) | 5.6 ± 64.69 | -9.5 ± 16.27 | -13.3 ± 18.26 | -1.8 ± 20.71 |
| Diarrhoea: Wk 49 (n=4,4,4,10) | -8.3 ± 16.67 | -0.0 ± 27.22 | 16.7 ± 57.74 | -3.3 ± 18.92 |
| Fin. diff: Wk 25 (n=6,7,5,19) | 16.7 ± 49.95 | 19.0 ± 32.53 | 20.0 ± 50.55 | 8.8 ± 24.45 |
| Fin. diff: Wk 49 (n=4,4,4,10) | 8.3 ± 63.10 | 25.0 ± 31.91 | 0.0 ± 27.22 | 3.3 ± 18.92 |
Racc: Accumulation ratio calculated as AUC0-12h on Week 9 Day 1 divided by AUC0-12h on Week 1 Day 1 \[fold\]
| ratio | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| LDE225 (Week 9, Day 1) (n=4,6,3,13) | 4.60 (2.61 to 7.03) | 7.40 (4.38 to 19.6) | 10.9 (6.41 to 17.0) | 4.75 (1.84 to 20.0) |
T1/2: Elimination half-life associated with the terminal slope (lambda_z) of a semi logarithmic concentration-time curve \[time\]
| hour (h) | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Phase Ib and Phase II: INC424: PK Parameter: T1/2 | 1.81 (1.66 to 3.65) | 2.42 (1.28 to 3.14) | 2.20 (1.96 to 2.84) | 1.99 (1.34 to 3.10) |
Vss/F: Apparent volume of distribution at steady state after oral administration \[volume\]
| Litre (L) | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) |
|---|---|---|---|---|
| Phase Ib and Phase II: INC424: PK Parameter: Vss/F | 63.7 (44.5 to 86.5) | 67.1 (41.0 to 75.7) | 53.1 (47.7 to 80.5) | 54.5 (22.9 to 102) |
Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 1505 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225 400 mg + INC424 10 mg | 1/8 (12.5%) | 5/8 (62.5%) | 8/8 (100%) |
| LDE225 400 mg + INC424 15 mg | 1/10 (10%) | 6/10 (60%) | 10/10 (100%) |
| LDE225 400 mg + INC424 20 mg | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| LDE225 400 mg + INC424 20 mg (Dose Expansion) | 1/27 (3.7%) | 13/27 (48.1%) | 27/27 (100%) |
| All Patients | 4/50 (8%) | 26/50 (52%) | 50/50 (100%) |
| Event | LDE225 400 mg + INC424 10 mg | LDE225 400 mg + INC424 15 mg | LDE225 400 mg + INC424 20 mg | LDE225 400 mg + INC424 20 mg (Dose Expansion) | All Patients |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/8 | 0/10 | 0/5 | 3/27 | 5/50 |
| Gastric ulcerGastrointestinal disorders | 0/8 | 0/10 | 1/5 | 0/27 | 1/50 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/8 | 2/10 | 0/5 | 0/27 | 2/50 |
| Blood creatine phosphokinase increasedInvestigations | 0/8 | 2/10 | 0/5 | 3/27 | 5/50 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/10 | 1/5 | 1/27 | 2/50 |
| Atrial fibrillationCardiac disorders | 1/8 | 0/10 | 0/5 | 0/27 | 1/50 |
| Right ventricular failureCardiac disorders | 1/8 | 0/10 | 0/5 | 0/27 | 1/50 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 1/8 | 0/10 | 0/5 | 0/27 | 1/50 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/8 | 0/10 | 0/5 | 0/27 | 1/50 |
| Face oedemaGeneral disorders | 1/8 | 0/10 | 0/5 | 0/27 | 1/50 |
| Event | LDE225 400 mg + INC424 10 mg | LDE225 400 mg + INC424 15 mg | LDE225 400 mg + INC424 20 mg | LDE225 400 mg + INC424 20 mg (Dose Expansion) | All Patients |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/8 | 4/10 | 4/5 | 16/27 | 29/50 |
| DiarrhoeaGastrointestinal disorders | 3/8 | 3/10 | 4/5 | 11/27 | 21/50 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/8 | 6/10 | 4/5 | 18/27 | 31/50 |
| FatigueGeneral disorders | 6/8 | 3/10 | 0/5 | 8/27 | 17/50 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/8 | 7/10 | 3/5 | 12/27 | 25/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/8 | 2/10 | 3/5 | 7/27 | 15/50 |
| Blood creatine phosphokinase increasedInvestigations | 1/8 | 2/10 | 3/5 | 12/27 | 18/50 |
| DysgeusiaNervous system disorders | 3/8 | 4/10 | 3/5 | 9/27 | 19/50 |
| PyrexiaGeneral disorders | 0/8 | 2/10 | 2/5 | 7/27 | 11/50 |
| NasopharyngitisInfections and infestations | 0/8 | 2/10 | 2/5 | 2/27 | 6/50 |
| Age, Continuous(Years) | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15 mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) | Total |
|---|---|---|---|---|---|
| Mean | 70.9 ± 5.19 | 59.9 ± 11.59 | 64.6 ± 13.18 | 67.4 ± 10.02 | 66.2 ± 10.42 |
| Sex: Female, Male(Participants) | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15 mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 1 | 8 | 15 |
| Male | 7 | 5 | 4 | 19 | 35 |
| Race (NIH/OMB)(Participants) | LDE225 400mg + INC424 10 mg (Dose Escalation Phase) | LDE225 400mg + INC424 15 mg (Dose Escalation Phase) | LDE225 400mg + INC424 20mg (Dose Escalation Phase) | LDED225 400mg + INC424 20mg (Dose Expansion Phase) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 10 | 5 | 26 | 47 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Supporting information: Study protocol, Statistical analysis plan
Ran from May 2013 to primary completion in Apr 2018, 59 months.
Results were first posted in Apr 2020, 2 years after primary completion.
Of 26 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's 59 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib